Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 20/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 15/20 | 0.54 |
| ▸ | PRKCA | P17252 | 9/20 | 0.45 |
| ▸ | PRKCB | P05771 | 2/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.40 |
| ▸ | PRKCG | P05129 | 1/20 | 0.40 |
| ▸ | PRKCH | P24723 | 1/20 | 0.40 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14718095 | 0.92 | PRKCQ (0.54) | PRKCQPRKCDPRKCAPRKCBPRKCE | |
| SCHEMBL12347381 | 0.92 | PRKCQ (0.54) | PRKCQPRKCDPRKCAPRKCBPRKCE | |
| SCHEMBL14725879 | 0.90 | PRKCQ (0.58) | PRKCQPRKCDPRKCAPRKCBPRKCE | |
| SCHEMBL14725880 | 0.85 | PRKCQ (0.56) | PRKCQPRKCDPRKCAPRKCBPRKCE | |
| SCHEMBL9882086 | 0.83 | PRKCQ (0.58) | PRKCQPRKCDPRKCAPRKCBPRKCE | |
| SCHEMBL9882058 | 0.81 | PRKCQ (0.74) | PRKCQPRKCDPRKCAPRKCBPRKCE | |
| SCHEMBL9882140 | 0.81 | PRKCQ (0.74) | PRKCQPRKCDPRKCAPRKCBPRKCE | |
| SCHEMBL22428968 | 0.79 | PRKCQ (0.52) | PRKCQPRKCDPRKCAPRKCBPRKCE | |
| SCHEMBL14725882 | 0.79 | PRKCQ (0.50) | PRKCQPRKCDPRKCAPRKCBPRKCE | |
| SCHEMBL9881984 | 0.77 | PRKCQ (0.53) | PRKCQPRKCDPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | EpiAxis Therapeutics Pty Ltd. (AU) | 2017-09-21 | — | — | US | disclosed |
| US-20160354367-A1 | Stem Cell Modulation II | UNIVERSITY OF CANBERRA (AU) | 2016-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266140-A1 | Compositions for Modulating Cancer Stem Cells and Uses Therefor | PRKCQ, PRKCG, PRKCH | PRKCQ 1/4885PRKCD 12/4885PRKCA 5/4885 |
| US-20160354367-A1 | Stem Cell Modulation II | PRKCQ, PRKCI, PRKCG | PRKCQ 1/4885PRKCD 9/4885PRKCA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.